Almost a third of FTSE 100 cut or scrap dividends
15th Apr 2020 12:01
(Sharecast News) - Almost one-third of FTSE 100 companies have cut or scrapped their dividends during the coronavirus crisis, leaving investors relying on 10 companies for two-thirds of the index's likely payouts in 2020, research shows.
Read moreAstraZeneca surges on Covid-19 drug trial
14th Apr 2020 08:40
(Sharecast News) - AstraZeneca shares surged on Tuesday after the pharmaceuticals giant said it will start a clinical trial to assess the potential of Calquence (acalabrutinib) in the treatment of the exaggerated immune response associated with Covid-19 in severely ill patients.
Read moreMonday broker round-up
6th Apr 2020 12:43
(Sharecast News) - Anglo American: RBC Capital Markets downgrades to sector perform with a target price of 1,500p.
Read moreUK cough and cold medicine prices rise 10.7%
2nd Apr 2020 14:42
(Sharecast News) - The price of cough and cold medicine rose by 10.7% last week as retailers take advantage of the rise in demand due to the coronavirus outbreak.
Read moreAstraZeneca gets FDA approval, stops kidney drug trial after 'overwhelming efficacy'
30th Mar 2020 08:11
(Sharecast News) - Biopharmaceutical giant AstraZeneca said on Monday that two of its top-selling drugs had shown advances in the treatment of deadly diseases.
Read moreAstraZeneca hyperkalaemia drug gets approval in Japan
26th Mar 2020 09:29
(Sharecast News) - AstraZeneca said on Thursday that its Lokelma drug has been approved in Japan for the treatment of patients with hyperkalaemia - elevated levels of potassium in the blood.
Read moreAstraZeneca's Lynparza gets new orphan designation in Japan
19th Mar 2020 13:38
(Sharecast News) - AstraZeneca announced on Thursday that Lynparza, or 'olaparib', has been granted orphan drug designation in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively unresectable pancreatic cancer.
Read moreTuesday broker round-up
17th Mar 2020 13:00
(Sharecast News) - Ti Fluid Systems: Citigroup downgrades to neutral with a target price of 140p.
Read moreAstraZeneca posts mixed update on lung cancer drug R&D
17th Mar 2020 09:02
(Sharecast News) - Pharmaceuticals giant AstraZeneca issued a mixed update on recent research and development work on Tuesday.
Read moreTrump set to declare national emergency in US, freeing up funding
13th Mar 2020 16:53
(Sharecast News) - The US is expected to declare a national emergency at the end of the week and call for a coordinated international response to contain the coronavirus and its economic fallout.
Read moreAstraZeneca reports disappointing results from latest 'Lynparza' trial
12th Mar 2020 07:32
(Sharecast News) - AstraZeneca, alongside its partner MSD, announced high-level results from the phase 3 'GY004' trial on Thursday, which examined the efficacy and safety of the potential new medicine 'cediranib' added to 'Lynparza', or olaparib, when compared to platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer.
Read moreAstraZeneca bladder treatment fails to met trial endpoint
6th Mar 2020 07:19
(Sharecast News) - AstraZeneca said its Imfinzi bladder cancer treatment did not meet primary endpoints in the phase three DANUBE trial against standard-of-care (SoC) chemotherapy for patients with an advanced stage of the disease.
Read moreTuesday broker round-up
25th Feb 2020 13:15
(Sharecast News) - Redrow: Jefferies upgrades to buy with a target price of 981p.
Read moreAstraZeneca offloads 'Movantik' rights to RedHill Biopharma
25th Feb 2020 07:30
(Sharecast News) - AstraZeneca has agreed to sublicense its global rights to 'Movantik', or naloxegol, excluding Europe, Canada and Israel, to RedHill Biopharma, it announced on Tuesday.
Read moreThursday broker round-up
20th Feb 2020 13:40
(Sharecast News) - Travis Perkins: Citigroup upgrades to buy with a target price of 1,900p.
Read more